A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

被引:40
|
作者
Zhong, Runbo [1 ]
Han, Baohui [1 ]
Zhong, Hua [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Dis, Shanghai 200030, Peoples R China
关键词
Chemoimmunotherapy; Dendritic cell; Cytokine-induced killer cell; Non-small cell lung cancer;
D O I
10.1007/s13277-013-1132-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cells (DC) play a crucial role in the induction of an effective antitumor immune response. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes, have the capacity to eliminate cancer cells. This study was to evaluate the correlation between the frequency of DC/CIK immunotherapies following regular chemotherapy, the time-to-progression (TTP), and overall survival (OS) of advanced non-small lung cancer patients. Sixty patients with IIIB-IV non-small-cell lung carcinoma (NSCLC) were enrolled from August 2007 to December 2009 and were randomized into two groups. All 60 patients received four courses of navelbine-platinum (NP) chemotherapy. In one group, 30 patients were treated with adoptive autologous DC/CIK cell transfusion twice every 30 days. In the other group, the patients received immunotherapies more than twice every 30 days. The adverse effects, TTP, and OS were evaluated between the two groups. Median survival time of all 60 patients was 13.80 months. The 1-, 2-, and 3-year overall survival rates were 60.0, 21.7, and 15.0 %, respectively. The 1-, 2-, and 3-year overall survival rates of patients receiving more than two immunotherapies were 63.3, 30.0, and 23.3 %, and the rates of those receiving two immunotherapies were 56.7, 13.3, and 6.7 %, respectively. The difference between the two groups was statistically significant (P = 0.037). Compared with patients in the fewer immunotherapies group, TTP in the group receiving more immunotherapies significantly prolonged, with the median improving from 6.2 months (95 % CI, 5.35-9.24) to 7.3 months (95 % CI, 5.45-6.95; P = 0.034). The adverse effects of chemoimmunotherapy were tolerable. Advanced NSCLC patients can benefit from the combination of DC/CIK immunotherapies following conventional chemotherapy. More than two immunotherapies improved TTP and OS of those patients in this study.
引用
收藏
页码:987 / 994
页数:8
相关论文
共 50 条
  • [31] Optimizing chemotherapy for patients with advanced non-small cell lung cancer
    Scagliotti, Giorgio
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) : S86 - S91
  • [32] Chemotherapy in elderly patients with advanced non-small cell lung cancer
    Quoix, Elisabeth
    Westeel, Virginie
    Zalcman, Gerard
    Milleron, Bernard
    LUNG CANCER, 2011, 74 (03) : 364 - 368
  • [33] Chemotherapy of advanced non-small cell lung cancer
    Jassem, J
    ANNALS OF ONCOLOGY, 1999, 10 : 77 - 82
  • [34] The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites
    Ai, Yue-Qin
    Cai, Kai
    Hu, Jian-Hua
    Jiang, Long-Wei
    Gao, Yan-Rong
    Zhao, Hua
    Jia, Shao-Chang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (11): : 4272 - 4281
  • [35] Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation
    Martins, RG
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 26 (03) : 273 - 277
  • [36] Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
    Wei, Zhigang
    Ye, Xin
    Yang, Xia
    Zheng, Aimin
    Huang, Guanghui
    Li, Wenhong
    Ni, Xiang
    Wang, Jiao
    Han, Xiaoying
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2015, 38 (01) : 135 - 142
  • [37] Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis
    Zhou, Xiuling
    Mo, Xiangqiong
    Qiu, Junlan
    Zhao, Jingjing
    Wang, Shuncong
    Zhou, Cuiling
    Su, Yonghui
    Lin, Zhong
    Ma, Haiqing
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 5363 - 5372
  • [38] Detecting circulating tumor cells in patients with advanced non-small cell lung cancer
    Xu, Y. H.
    Zhou, J.
    Pan, X. F.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (03) : 10352 - 10358
  • [39] Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer
    Pujol, JL
    Quantin, X
    Choma, D
    Jacot, W
    Khial, F
    LUNG CANCER, 2002, 38 : S57 - S60
  • [40] Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
    Zhigang Wei
    Xin Ye
    Xia Yang
    Aimin Zheng
    Guanghui Huang
    Wenhong Li
    Xiang Ni
    Jiao Wang
    Xiaoying Han
    CardioVascular and Interventional Radiology, 2015, 38 : 135 - 142